厄贝沙坦治疗糖尿病蛋白尿的临床效果

Clinical Effect of Irbesartan in the Treatment of Diabetic Proteinuria

目的分析厄贝沙坦治疗糖尿病蛋白尿的临床效果。方法选取2018年3月—2019年4月该院收治的糖尿病蛋白尿患者76例为研究对象,随机单双数法分为对照组38例,进行常规治疗,观察组38例,予以厄贝沙坦治疗,对比患者治疗效果、不良反应率。结果治疗前两组患者尿微量白蛋白等指标均差异无统计学意义(P>0.05);治疗后观察组患者尿微量白蛋白显著低于对照组,差异有统计学意义(P<0.05);治疗后两组患者BUN(血尿素氮)、Scr(血肌酐)、K^+(血清钾)差异无统计学意义(P>0.05);两组患者不良反应率无,差异无统计学意义(P>0.05);观察组患者总有效率显著高于对照组,差异有统计学意义(P<0.05)。结论糖尿病蛋白尿患者予以厄贝沙坦干预后总有效率有显著提升,且蛋白尿得到控制,不良反应较少,有应用价值。

Objective To analyze the clinical effect of irbesartan in the treatment of diabetic proteinuria.Methods A total of 76 diabetic proteinuria patients admitted in the hospital from March 2018 to April 2019 were selected as the research subjects.The random odd and even number method was used to divide the control group into 38 cases for routine treatment and the observation group for 38 cases.The treatment was compared with the treatment effect and adverse reaction rate.Results There was no significant difference in urine microalbumin and other indicators between the two groups of patients before treatment,and there was no statistical significance(P>0.05).The urine microalbumin in the observation group was significantly lower than that in the control group after treatment,and the difference was statistically significant(P<0.05);After treatment,BUN(blood urea nitrogen),Scr(blood creatinine),K^+(serum potassium)were not significantly different between the two groups,there was no statistical significance(P>0.05);there was no statistically significant difference in adverse reaction rates between the two groups.The difference was not statistically significant(P>0.05);the total effective rate of patients in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The total effective rate of diabetic proteinuria patients is significantly improved after intervention with irbesartan,and proteinuria is controlled,with fewer adverse reactions,and has application value.